LifeMD (NASDAQ:LFMD) Lowered to “Sell” at Zacks Investment Research
According to Zacks, “LifeMD Inc. is a telehealth company. It offers a full portfolio of direct-to-patient products and services. The company combines virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers. LifeMD Inc., formerly known as Conversion Labs, is based in NEW YORK. “
LFMD stock opened at $16.25 on Wednesday. LifeMD has a 12-month low of $1.20 and a 12-month high of $33.02.
In other LifeMD news, COO Brad Michael Roberts purchased 5,000 shares of the business’s stock in a transaction dated Thursday, February 25th. The shares were acquired at an average price of $20.50 per share, for a total transaction of $102,500.00.
LifeMD Company Profile
LifeMD, Inc operates as a telemedicine company with a portfolio of online direct-to-consumer brands. The company combines virtual medical treatment with prescription medications and over-the-counter products. Its network of physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S.
Read More: Why Invest in High-Yield Dividend Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.